Mr. Peter Bains is the Group CEO for Biocon. In this role, he is responsible for driving synergies between the three group entities — Biocon Limited representing the Generics and Novel Biologics segments, Biocon Biologics Limited representing the Biosimilars segment and Syngene International Limited representing the Research Services segment — to maximize the combined value for the stakeholders, at the group level.
Peter will be responsible for maximising benefits from the combined manufacturing and project execution capabilities, deep scientific knowhow, global best practices and knowledge sharing across all group entities. Leveraging the synergies between the three Biocon Group companies will create further value for all stakeholders.
Peter has extensive global experience in strategic and operational leadership including at the Board, CEO and Senior Corporate Leadership levels.
He has an extensive and proven track record of success in building companies, businesses, teams and brands for over 30 years. His experience in biopharmaceuticals straddle business and technology segments (biotechnology, vaccines, branded generics, life sciences, CRO) and geographies encompassing both advanced and emerging markets.
Peter has a comprehensive understanding of the Biocon Group. He served as CEO and on the Board of Syngene for almost six years starting 2010 and led the company to its successful public listing in 2015.
At present, Peter is the Non-Executive Director on the Board of Indivior PLC, a UK FTSE-listed pharmaceuticals company; MiNA Therapeutics, a privately held UK biotech company and world leader in small activating RNA technology; and Apterna, a privately held UK biotech engaged in aptamer discovery. He is also Non-Executive Chairman of ILC Therapeutics, a privately held Scottish biotechnology company.
Peter has served as CEO of Sosei Group, a Japanese listed biopharmaceutical company. Prior to this, Peter worked with GlaxoSmithKline over a period of 23 years, where he held several roles including Head of Global Marketing and Senior Vice President of commercial development for GSK’s international region.
Peter holds a bachelor’s degree in Science (combined honours in Zoology and Physiology) from the University of Sheffield, UK.